Trials / Approved For Marketing
Approved For MarketingNCT03147742
An Expanded Access Program of Ruxolitinib for the Treatment of Graft-Versus-Host Disease Following Allogeneic Hematopoietic Stem Cell Transplant
An Open-Label, Expanded Access Program of Ruxolitinib for the Treatment of Graft-Versus-Host Disease Following Allogeneic Hematopoietic Stem Cell Transplant
- Status
- Approved For Marketing
- Phase
- —
- Study type
- Expanded Access
- Enrollment
- —
- Sponsor
- Incyte Corporation · Industry
- Sex
- All
- Age
- 12 Years
- Healthy volunteers
- —
Summary
To provide ruxolitinib through an expanded access program for the treatment of graft-versus-host disease (GVHD) in United States to patients who are ineligible or unable to participate in any actively enrolling Incyte-sponsored clinical studies for ruxolitinib in the treatment of GVHD.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Ruxolitinib | Ruxolitinib starting dose level 10 mg orally, twice daily (BID). |
Timeline
- First posted
- 2017-05-10
- Last updated
- 2022-06-07
Locations
33 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT03147742. Inclusion in this directory is not an endorsement.